Kainen Health: Plans to Invest Over 80 Million Yuan to Collaborate with Sichuan Provincial People's Hospital on Clinical Research in Cell Therapy

LightningPacketLoss · 2026-03-18T09:55:37+00:00

Kainen Health Technology Group has signed a five-year cooperation agreement with the Sichuan Academy of Medical Sciences, planning to invest 80 million yuan in stem cell and immune cell therapy research and development. The cooperation will focus on orthopedics, ophthalmology, and age-related diseases, aiming to advance the transformation of cell therapy achievements and enhance the company's competitiveness, though project progress carries uncertainties.

LightningPacketLoss

2026-03-18 09:55:37

Abstract generation in progress

Recently, Kaineng Health Technology Group announced that its subsidiary, Shanghai Yuan Tian Biotechnology, has signed a five-year “Letter of Intent for Cooperation” with Sichuan Provincial Medical Academy of Sciences and Sichuan Provincial People’s Hospital. During the cooperation period from 2026 to 2030, Kaineng Health will invest no less than 80 million yuan in phases for research and development projects.

The two parties will focus on orthopedics, ophthalmology, and age-related diseases, collaborating on GCP and IIT projects involving stem cells and immune cell preparations. They will jointly explore clinical translation pathways for cell therapy, accumulate safety and efficacy data, and promote the transformation of results into advanced treatment methods. Kaineng Health stated that the related investments will be made according to the actual progress of the projects. It is expected that these will not significantly impact current operating performance but will help enhance the company’s core competitiveness in cell research and application fields. However, due to the complexity and various factors affecting the scientific research projects, there are uncertainties.

(Kaineng Health Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.